MORE posts
Taryn Dailey-Govoni, Jared Beaumont, Theresa Cassidy Inflexxion, Inc., Waltham, MA, USA Presented at PAINWeek 2017 Read our poster for “Profiling non-medical use of tapentadol products among recreational drug abusers” here Abstract Purpose Prescription opioid misuse and abuse is a public health epidemic in the United States (ONDCP 2015) and a growing source of morbidity, mortality, […]
Inflexxion, Inc. announced today that Allscripts has certified PainCAS™ as part of the Allscripts Developer Program. PainCAS enables Allscripts ambulatory EHR users to assess pain, functioning, and risk of problematic opioid-related behaviors in patients with chronic pain. Developed in part with support from the National Institutes of Health (NIH), grants (Grant No. R44DA026359, PI S.F. Butler and Grant No. R44DA015617, PI S.F. Butler), PainCAS is a scientifically validated web-based, patient self-report clinical tool for assessing pain and opioid misuse risk in patients with chronic pain.
Jared Beaumont, M.P.H.1, Theresa Cassidy, M.P.H.1, Taryn Dailey Govoni, M.P.H.1 Presented at International Conference on Opioids 2017 See our poster for “Abuse and route of administration prevalence for tapentadol products within the NAVIPPRO® ASI-MV® surveillance system” here Abstract Post-market surveillance data indicate low abuse levels of tapentadol products, but research regarding the route of administration […]
Theresa A. Cassidy, MPH, Natasha K. Oyedele, MPH, Jared Beaumont, MPH, Stephen F. Butler, PhD Presented at PAINWeek 2015 See our poster for “Patterns of abuse of hydrocodone combination products: Results from an Internet survey of recreational drug users” here Summary: Researchers conducted this study to examine the progression of hydrocodone combination products (HCP) abuse, routes of administration, and […]
Authors: Trudeau, K. J.; Pujol, L. A.; DasMahapatra, P.; Wall, R.; Black, R. A.; Zacharoff, K Journal of Behavioral Medicine, June 2015, Volume 38, Issue 3, pp 483–496 Abstract The objective of this RCT was to assess the efficacy of an online pain self-management program with adults who had a self-reported doctor diagnosis of arthritis pain (N = 228). Participants were recruited […]
Theresa A. Cassidy, Jared Beaumont, Veronica Urdaneta, Simon H. Budman, Stephen F. Butler Presented at PAINWeek 2014 See our poster for “The changing abuse ecology: implications for evaluating the abuse pattern of extended-release oxymorphone and abuse-deterrent opioid formulations” here Abstract Purpose FDA Guidelines released in January 2013 on evaluating abuse-deterrent formulations (ADFs) recommend direct comparison […]
Stephen F. Butler, PhD, Theresa A. Cassidy, MPH, Taryn Dailey, BA1, & Paul M. Coplan, ScD2, Presented at CPDD 2014 See our poster for “Comparing abuse of extended-release versus immediate-release opioid analgesics adjusted for number of prescriptions and morphine-equivalent dose” here Abstract Aims: It has been suggested that abuse risk of extended-release (ER) opioids is […]
Authors: Cassidy, T. A.; DasMahapatra, P.; Black, R. A.; Wieman, M. S.; Butler, S. F. Pain Medicine, 15: 440–451. doi:10.1111/pme.12295, 2014 Abstract Objective The reformulation of oxycodone hydrochloride controlled-release (CR) tablets in August 2010 created a natural experiment at a national scale, providing an opportunity to evaluate patterns of abuse of prescription opioids and other drugs […]
Authors: Zaller, N.; Yokell, M. A.; Green, T. C. Substance Use & Misuse, Volume 48, 2013 – Issue 8 Abstract This study analyzed qualitative data from a Rapid Policy Assessment and Response project to assess the feasibility of a potential pharmacy-based naloxone intervention to reduce opioid overdose mortality among injection drug users (IDUs). We conducted in-depth, […]
Theresa A. Cassidy, MPH, Emily C. McNaughton, MPH , Kimberly Lobo, MPH , Simon H. Budman, PhD, Stephen F. Butler, PhD Presented at American Society of Addiction Medicine (ASAM), Chicago, IL, April 25-27th, 2013 See our poster for “Abuse of Reformulated OPANA® ER: early findings from NAVIPPRO® data” here Abstract Summary: Reformulated extended release (ER) oxymorphone (OPANA […]
Based on a recent study, our team has published an article in the “Journal of Pain” titled, “Abuse rates and routes of administration of reformulated extended release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.” To access the full text, click here. Abstract Oxycodone hydrochloride controlled-release, also known […]
Theresa A. Cassidy, MPH, Emily C. McNaughton, MPH , Stephen F. Butler, PhD, Simon H. Budman, PhD Presented at PAINWeek 2012 See our poster for “Change in prescription opioid abuse after introduction of an abuse deterrent formulation” here Abstract OBJECTIVE: The reformulation of oxycodone hydrochloride controlled-release (CR) tablets in August 2010 created a natural experiment […]